Blastic natural killer cell lymphoma was first discovered by Adachi, an American hematologist, in 1994 following an unusual presentation of cutaneous lymphoma that express CD4 and CD56 antigens but no other T cell and B cell antigens. The deletion in 5q has been associated with the development of blastic natural killer cell lymphoma. Blastic natural killer cell lymphoma must be differentiated from other malignancies such as acute myeloid leukemia, human T-cell lymphotropic virus 1 associated adult T-cell leukemia/lymphoma, cutaneous<unk> /T-cell lymphoma, primary and secondary cutaneous pleomorphic T-cell lymphomas, undifferentiated carcinoma, and malignant melanoma.<unk>  is more commonly observed among middle-aged or elderly patients. The mean age at diagnosis is 66 years.Males are more commonly affected with blastic natural killer cell lymphoma than females. Prognosis is generally poor, and the median survival rate is 15 months. Symptoms of blastic natural killer cell lymphoma may include nodules, plaques and patches of variable sizes on skin. Immunohistochemical staining is positive for r CD4 and CD56, with variable positivity for CD43, TdT, and CD68. The mainstay of therapy for blastic natural killer cell lymphoma is chemotherapy with CHOP or COP-like regimens.
Blastic NK cell lymphoma
Angioimmunoblastic T-cell lymphoma
Extranodal NK-T-cell lymphoma
Peripheral T cell lymphoma
Anaplastic large cell lymphoma
Nodal marginal zone lymphoma
Aggressive NK-cell leukemia
Mantle cell lymphoma